SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2282196
下载链接
链接失效反馈官方服务：
资源简介：
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody.
The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.
创建时间：
2018-11-15
